Elizabeth Chun

Elizabeth Chun, PhD

Research Associate in Biomedical Informatics

Elizabeth (Hye-Jung) Chun received her MSc and PhD in Bioinformatics (under the supervisions of Drs. Steven Jones and Marco Marra, respectively) from the University of British Columbia, Canada. As part of the NIH NCI’s Therapeutically Applicable Research that Generates Effective Therapy (TARGET) initiative, Chun’s doctoral research focused on molecular characterization of pediatric malignant rhabdoid tumors (MRTs) through integrative analyses of whole genome, transcriptome, DNA methylation and histone modification profiles. Her work led to identification of novel molecular subgroups and revealed potential application of immunotherapy in this cancer type with very few mutations. She continued her research as a postdoctoral research fellow in Dr. Marra’s lab, to identify genetic and epigenetic alterations in MRTs using long-read sequencing data. Prior to her graduate training, she worked as a computational biologist at Canada’s Michael Smith Genome Sciences Centre, performing data analyses and coordinating research activities for The Cancer Genome Atlas (TCGA) and the Development of Highly active Anti-Leukemia stem cell Therapy at California Institute of Regenerative Medicine (CIRM-HALT) projects. She joined the Park Lab in June 2022. In the Park Lab, she is continuing her research in cancer genomics and contributing her work in the Common Fund Data Ecosystem project.

Comprehensive molecular characterization of gastric adenocarcinoma.

Nature
View full abstract on Pubmed
Comprehensive molecular characterization of clear cell renal cell carcinoma.

Nature
View full abstract on Pubmed
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.

N Engl J Med
View full abstract on Pubmed
Integrated genomic characterization of endometrial carcinoma.
Authors: Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA.
Nature
View full abstract on Pubmed
A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition.
Authors: Goff DJ, Court Recart A, Sadarangani A, Chun HJ, Barrett CL, Krajewska M, Leu H, Low-Marchelli J, Ma W, Shih AY, Wei J, Zhai D, Geron I, Pu M, Bao L, Chuang R, Balaian L, Gotlib J, Minden M, Martinelli G, Rusert J, Dao KH, Shazand K, Wentworth P, Smith KM, Jamieson CA, Morris SR, Messer K, Goldstein LS, Hudson TJ, Marra M, Frazer KA, Pellecchia M, Reed JC, Jamieson CH.
Cell Stem Cell
View full abstract on Pubmed
ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia.
Authors: Jiang Q, Crews LA, Barrett CL, Chun HJ, Court AC, Isquith JM, Zipeto MA, Goff DJ, Minden M, Sadarangani A, Rusert JM, Dao KH, Morris SR, Goldstein LS, Marra MA, Frazer KA, Jamieson CH.
Proc Natl Acad Sci U S A
View full abstract on Pubmed
Comprehensive molecular portraits of human breast tumours.

Nature
View full abstract on Pubmed
Comprehensive genomic characterization of squamous cell lung cancers.

Nature
View full abstract on Pubmed
Comprehensive molecular characterization of human colon and rectal cancer.

Nature
View full abstract on Pubmed
A conifer genomics resource of 200,000 spruce (Picea spp.) ESTs and 6,464 high-quality, sequence-finished full-length cDNAs for Sitka spruce (Picea sitchensis).
Authors: Ralph SG, Chun HJ, Kolosova N, Cooper D, Oddy C, Ritland CE, Kirkpatrick R, Moore R, Barber S, Holt RA, Jones SJ, Marra MA, Douglas CJ, Ritland K, Bohlmann J.
BMC Genomics
View full abstract on Pubmed